Clearwater acquires Enfusion for $1.5B

0
158

Clearwater’s CEO, Sandeep Sahai, expressed his excitement about the future of the merger. “Today’s announcement is about creating a future where our clients benefit from the synergy of two highly complementary, innovative software leaders,” Sahai said. “This acquisition enables seamless data management from the front office to the back office, unlocking powerful network effects that amplify client value.”

Two Giants, One Unified Vision

Clearwater, a leading provider of Software-as-a-Service (SaaS) solutions that automate the entire investment lifecycle, is set to integrate Enfusion’s real-time, enterprise-wide data capabilities with its own suite of middle and back-office solutions. This integration aims to create a seamless front-to-back platform that will cater to the evolving needs of institutional investors, transforming how investment management is done.

Enfusion, a SaaS platform specializing in real-time data for investment managers, has long been known for its versatility, scalability, and deep functionality, serving both traditional and alternative investment sectors. Its CEO, Oleg Movchan, highlighted the potential of the combined forces. “Together with Clearwater, our shared passion for building innovative technologies will accelerate our ability to support our clients’ evolving needs, ensuring they stay at the forefront of investment management.”

Signup for the USA Herald exclusive Newsletter

Shareholder Approval and Future Outlook

The deal has garnered the support of Enfusion’s shareholders, with those holding around 45% of the company’s total voting power entering into voting and support agreements. The transaction is expected to close in the second quarter of 2025, pending approval by Enfusion’s shareholders, regulatory approval, and the usual closing conditions.

Legal Experts Behind the Deal

Clearwater’s legal team at Kirkland & Ellis was led by corporate partners Constantine Skarvelis, Marshall Shaffer, Jimin He, and Daniel Yip, with additional expertise from debt, tax, and capital markets specialists. Enfusion’s special committee was advised by Dechert’s corporate partners Mark E. Thierfelder, Eric S. Siegel, and Michael S. Darby, along with litigation experts Andrew J. Levander and Rick S. Horvath.